热景生物(688068) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥195,851,213.44, representing a year-over-year increase of 252.17%[3] - The net profit attributable to shareholders for Q3 2021 was ¥23,720,430.14, reflecting a significant increase of 660.26% compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥19,093,212.11, up 866.77% year-over-year[3] - The basic earnings per share for Q3 2021 was ¥0.38, up 660.26% from the same period last year[4] - Total operating revenue for the first three quarters of 2021 reached RMB 3,795,574,243.30, a significant increase from RMB 145,513,104.79 in the same period of 2020, representing a growth of approximately 2,505%[24] - Net profit for the first three quarters of 2021 was RMB 1,485,051,091.49, a decrease from RMB 3,341,163.56 in the previous year, reflecting a decline of approximately 56%[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,401,130,435.24, an increase of 166.05% compared to the end of the previous year[4] - The company's total assets as of September 30, 2021, amounted to RMB 2,401,130,435.24, compared to RMB 902,515,021.55 at the end of 2020, marking an increase of about 166%[20] - Current assets totaled RMB 1,779,047,363.59 as of September 30, 2021, compared to RMB 587,771,186.93 at the end of 2020, representing an increase of approximately 202%[20] - The total liabilities as of September 30, 2021, were RMB 247,585,111.43, compared to RMB 155,723,395.72 at the end of 2020, showing an increase of approximately 59%[21] - Total liabilities amounted to $155.72 million, an increase of $25.07 million compared to the previous period[34] Equity - The total equity attributable to shareholders at the end of the reporting period was ¥2,139,765,674.94, which is an increase of 188.10% year-over-year[4] - The company's equity attributable to shareholders reached RMB 2,139,765,674.94, up from RMB 742,728,503.81 at the end of 2020, representing an increase of about 187%[21] - Total equity reached $746.79 million, with retained earnings of $205.60 million[34] Research and Development - The company invested ¥22,347,643.31 in R&D during Q3 2021, which is an increase of 140.14% year-over-year[4] - R&D expenses accounted for 11.41% of operating revenue in Q3 2021, a decrease of 5.32 percentage points compared to the previous year[4] - The company invested a total of 82.75 million RMB in R&D from January to September 2021, a significant increase of 214.85% compared to the same period last year[14] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥1,351,716,713.42, showing a significant improvement from a net outflow in the same period last year[3] - The net cash flow from operating activities for the first three quarters of 2021 was ¥1,351,716,713.42, a significant improvement from a net outflow of ¥28,309,117.51 in the same period of 2020[29] - Cash received from the sale of goods and services was ¥3,807,118,501.83, compared to ¥133,755,975.94 in the previous year, indicating a substantial increase[28] - The net cash flow from investment activities was -¥1,318,409,445.79, worsening from -¥312,966,047.57 year-over-year[29] Market and Sales - The company attributed the revenue growth primarily to the expansion of its business scale and significant overseas sales of COVID-19 antigen test kits[9] - The company actively promoted its COVID-19 antigen detection products, leading to a surge in foreign trade orders[17] - The company strengthened its sales team and product variety, enhancing service capabilities in the domestic market[16] - The company has been focusing on expanding its market presence and brand recognition both domestically and internationally[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,214[11] - The top shareholder, Lin Changqing, holds 23.55% of the shares, while the second-largest shareholder, Zhou Xin, holds 8.48%[11] Intellectual Property - The company obtained 3 intellectual property rights in Q3 2021, including 1 PCT international patent and 1 invention patent[15] - The company has a total of 365 medical device registration certificates, with 163 in China and 202 internationally[15] Accounting Standards - The company adopted new leasing standards effective January 1, 2021, impacting financial statement presentation[35] - The company’s board announced the implementation of new accounting standards for leases starting January 1, 2021[35]